Thoratec to Present at Upcoming Investor Conferences
PLEASANTON, Calif., Nov. 22, 2010 /PRNewswire-FirstCall/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in two upcoming investor conferences.
On Tuesday, November 30, the company will participate in the 22nd Annual Piper Jaffray Health Care Conference. David V. Smith, executive vice president and chief financial officer, will provide an update on the company, beginning at 1 p.m., Eastern Standard Time (10 a.m., Pacific Standard Time). The presentation will be available through the conference web site at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=THOR&item_id=3494622 or on the company's web site at http://www.thoratec.com.
On Tuesday, December 7, Thoratec will participate in the 5th Annual Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference. The presentation by Gary F. Burbach, president and chief executive officer, will begin at 8 a.m., Pacific Standard Time (11 a.m., Eastern Standard Time), and can be accessed through the conference web site at http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=3298900 or on the company's web site at http://www.thoratec.com.
Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's products include the HeartMate® LVAS (Left Ventricular Assist System) and Thoratec® VAD (Ventricular Assist Device) with more than 15,000 devices implanted in patients suffering from heart failure. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's web site at http://www.thoratec.com.
Thoratec, the Thoratec logo, HeartMate and HeartMate II are registered trademarks of Thoratec Corporation and IVAD is a trademark of Thoratec Corporation.
SOURCE Thoratec Corporation
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article